Serina Therapeutics Advances POZ-VMAT2i for Tardive Dyskinesia

Serina Therapeutics announced the advancement of SER-270 (POZ-VMAT2i), a novel, once-weekly injectable VMAT2 inhibitor, for treating tardive dyskinesi...
Home/KnloSights/Clinical Trial Updates/Serina Therapeutics Advances POZ-VMAT2i for Tardive Dyskinesia